MarketMoodz
CVS Caremark expands osteoporosis biosimilars strategy
CVS Caremark reportedly plans to expand its osteoporosis biosimilar list, adding candidates to major national formularies effective April 1, 2026. If confirmed, the shift could lower costs and press branded biologics from Amgen and Lilly, altering payer pricing dynamics and access for patients.
Key Takeaways
- CVS Caremark reportedly will add osteoporosis biosimilars to national formularies starting April 1, 2026, potentially replacing branded Prolia and Forteo.
- Biosimilars cited include Ospomyv/Stoboclo and Bonsity/Tymlos, with per-prescription costs described as more than 50% lower than the originals.
- CVS cites previous Humira substitutions as evidence of biosimilar savings, claiming $1.5 billion in gross savings and a 96% transition rate (data unconfirmed).
- Market reaction attributed to the report suggested CVS Health stock moved about 1.6% higher on the day, though independent price data is needed.
People Involved
- No specific individuals mentioned
Entities Involved
- CVS Health CorpParent company of CVS Caremark and payer/retail pharmacy operator
- Cordavis LimitedBiosimilar developer mentioned as producer of Ospomyv
- Celltrion Inc.Biosimilar producer mentioned as developer of Stoboclo
- AmgenMaker of Prolia (denosumab)
- Eli LillyMaker of Forteo (teriparatide)
- AbbVieMaker of Humira
MarketMoodz Analysis
The reported shift would underscore payers’ growing leverage to steer drug spend toward biosimilars, potentially compressing near-term pricing power for branded osteoporosis biologics. If a large payer like CVS Caremark substitutes Prolia and Forteo with lower-cost biosimilars, net drug spend could fall, supporting better-margin outcomes for CVS while pressuring sponsor manufacturers on top-line growth.
Historically, biosimilars have faced slower uptake than small-molecule generics, even after regulatory approvals. Humira biosimilars, for example, have delivered meaningful savings but required time and market education to reach high substitution rates; CVS’s prior reference to $1.5 billion in savings and 96% uptake reflects a best-case payor outcome. Investors should watch for official confirmation, actual formulary terms, and real-world uptake, which will determine the magnitude of CVS’s savings and any spillover to the stock.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial